Patent classifications
C12Q1/6809
METHOD OF DETECTION
The present invention relates to a method of detecting specific nucleic acid sequences and a device for performing the method therein. The specific nucleic acid may be prepared from a subject-specimen or from an environmental specimen and the method is performed in isothermal conditions.
METHOD OF DETECTION
The present invention relates to a method of detecting specific nucleic acid sequences and a device for performing the method therein. The specific nucleic acid may be prepared from a subject-specimen or from an environmental specimen and the method is performed in isothermal conditions.
DEVICES AND METHODS FOR GENOMIC STRUCTURAL ANALYSIS
Disclosed are methods for generating physical maps from feature density profiles of a nucleic acid using a constriction device, and associated methods of analyzing said genomic profiles. In addition, disclosed are devices and methods for analyzing secondary, tertiary and quaternary structures on nucleic acids in spatial and temporal context of the 3-D organization of the genome in a constriction or sensor device.
DEVICES AND METHODS FOR GENOMIC STRUCTURAL ANALYSIS
Disclosed are methods for generating physical maps from feature density profiles of a nucleic acid using a constriction device, and associated methods of analyzing said genomic profiles. In addition, disclosed are devices and methods for analyzing secondary, tertiary and quaternary structures on nucleic acids in spatial and temporal context of the 3-D organization of the genome in a constriction or sensor device.
IDENTIFICATION SYSTEM OF CIRCULATING BIOMARKERS FOR CANCER DETECTION, DEVELOPMENT METHOD OF CIRCULATING BIOMARKERS FOR CANCER DETECTION, CANCER DETECTION METHOD AND KIT
An identification system of circulating biomarkers for cancer detection, a development method of circulating biomarkers for cancer detection, a cancer detection method and a kit are provided in the present disclosure, and the development method includes the following steps. Expression levels of multiple genes in normal tissue samples and tumor tissue samples are identified, and genes with high expression levels in the tumor tissue samples are selected. Afterwards, a weight of each human tissue’s contribution to plasma exosomes is calculated using tissue-specific genes and group-enriched genes. Next, expression levels of plasma exosome genes of healthy people and cancer patients are compared by an overlapping index, and circulating biomarkers and combinations thereof suitable for detection and evaluation of plasma exosomes are selected.
Droplet-based method and apparatus for composite single-cell nucleic acid analysis
The present invention generally relates to a combination of molecular barcoding and emulsion-based microfluidics to isolate, lyse, barcode, and prepare nucleic acids from individual cells in a high-throughput manner.
Droplet-based method and apparatus for composite single-cell nucleic acid analysis
The present invention generally relates to a combination of molecular barcoding and emulsion-based microfluidics to isolate, lyse, barcode, and prepare nucleic acids from individual cells in a high-throughput manner.
Droplet-based method and apparatus for composite single-cell nucleic acid analysis
The present invention generally relates to a combination of molecular barcoding and emulsion-based microfluidics to isolate, lyse, barcode, and prepare nucleic acids from individual cells in a high-throughput manner.
Divalent nucleobase compounds and uses therefor
Described herein are novel divalent nucleobases that each bind two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone (a genetic recognition reagent, or genetic recognition reagent). In one embodiment, the genetic recognition reagent is a peptide nucleic acid (PNA) or gamma PNA (γPNA) oligomer. Uses of the divalent nucleobases and monomers and genetic recognition reagents containing the divalent nucleobases also are provided.
Divalent nucleobase compounds and uses therefor
Described herein are novel divalent nucleobases that each bind two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone (a genetic recognition reagent, or genetic recognition reagent). In one embodiment, the genetic recognition reagent is a peptide nucleic acid (PNA) or gamma PNA (γPNA) oligomer. Uses of the divalent nucleobases and monomers and genetic recognition reagents containing the divalent nucleobases also are provided.